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Abstract
Inflammation plays an important role in the development of cognitive decline and dementia in old age. Galectin-3 is known for its role
in acute and chronic inflammation. We assessed whether genetic variation in the LGALS3 gene, encoding for galectin-3, associates with
cognitive function in the 5804 participants of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). The rs4644, rs4652,
and rs1009977 polymorphisms were genotyped to cover the genomic region of the LGALS3 gene. Subjects carrying the variant alleles of
each LGALS3 single nucleotide polymorphism (SNP) had significantly higher baseline C-reactive protein concentrations (p 0.01). Carriers
of the variant alleles had significantly worse performance at baseline compared with carriers of the wild-type allele (all p  0.05). In the
ongitudinal analysis, we found that carriers of the variant alleles had worse performance at the attention tasks compared with carriers of
he wild-type allele. Although observed differences were small, these data suggest that genetic variation in the LGALS3 gene might be
ssociated with cognitive function in an elderly population. Further research is warranted to confirm these results.
2012 Elsevier Inc.
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Galectins are a family of animal lectins with affinity for
-galactosides (Dumic et al., 2006). They can interact with
cell-surface and extracellular matrix glycoproteins, through
lectin–carbohydrate interactions. Through this action, ga-
lectins promote cell growth, affect cell survival, modulate
cell adhesion, and induce cell migration. The most studied
family member is galectin-3 (Dumic et al., 2006). Galec-
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C-2-R, Leiden University Medical Center, PO Box 9600, 2300 RC, Leiden,
The Netherlands. Tel.: 31 71 526 6640; fax: 31 71 524 8159.E-mail address: s.trompet@lumc.nl (S. Trompet).
0197-4580 © 2012 Elsevier Inc.
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Open access under the Elsevier OA license.tin-3 is found in numerous cell and tissue types, and various
functions have been described, like promotion of macro-
phage migration, fibroblast proliferation, and collagen syn-
thesis (Dumic et al., 2006). However, the best known role
for galectin-3 is in acute and chronic inflammation (Hen-
derson and Sethi, 2009; Liu, 2005; Liu and Hsu, 2007)
because galectin-3-deficient mice have an attenuated in-
flammatory response with an increased number of inflam-
matory cells (Hsu et al., 2000).
In humans, galectin-3 has been associated with cancer
and cardiovascular disease (Lok et al., 2010), for which
inflammation is the common risk factor. Inflammation plays
also an important role in the development of cognitive
as
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Moreover, it has been shown in mouse models that galec-
tin-3 has a regulatory role in the brain. In experimental
studies of stroke, it has been shown that galectin-3 is over-
expressed by microglial cells and that after neuronal dam-
age, galectin-3 is upregulated (Doverhag et al., 2010). Fur-
thermore, galectin-3-deficient mice show protection from
ischemic injury, particularly in the hippocampus and stria-
tum (Doverhag et al., 2010). Finally, galectin-3 has been
located in the prefrontal cortex of hyperactive rats with
attention deficits (Wu et al., 2010). Because galectin-3 has
also regulating functions within the brain and especially in
the hippocampus, we hypothesize that galectin-3 may also
play a role in cognitive function.
We investigated the association between genetic varia-
tion in galectin-3 and cognitive function in participants of
the PROspective Study of Pravastatin in the Elderly at Risk
(PROSPER) (Shepherd et al., 2002). Because various stud-
ies have reported only moderate associations with systemic
inflammatory markers and cognitive decline, we concluded
that systemic markers are unlikely to be useful as risk
predictors for cognitive decline (Schram et al., 2007). On
the contrary, genetic markers are more likely to be a good
marker for risk prediction because associations with genetic
variations are assumed to be unconfounded. Therefore we
investigated the association between genetic variation in the
LGALS3 gene, encoding for galectin-3, and cognitive func-
tion in a prospective elderly cohort.
2. Methods
All data come from the PROSPER study. A detailed
description of the study has been published elsewhere
(Shepherd et al., 1999, 2002). A short summary is provided
here.
2.1. Participants
PROSPER was a prospective multicenter randomized
placebo-controlled trial to assess whether treatment with
pravastatin diminishes the risk of major vascular events in
the elderly. Between December 1997 and May 1999, we
screened and enrolled subjects in Scotland (Glasgow), Ire-
land (Cork), and the Netherlands (Leiden). Men and women
aged 70–82 years were recruited if they had pre-existing
vascular disease or increased risk of such disease because of
smoking, hypertension, or diabetes. A total number of 5804
subjects were randomly assigned to pravastatin or placebo.
A large number of prospective tests were performed includ-
ing laboratory and cognitive function measurements.
2.2. Genotyping
We selected three single nucleotide polymorphisms
(SNPs) in the LGALS3 gene, rs4644, rs4652, rs1009977
based on its minor allele frequency (5%) and their func-
tionality. These three polymorphisms tag the entire genomic iregion of the LGALS3 gene as identified in the HapMap
database and shown in Figure 1 (www.hapmap.org). All
SNPs were genotyped by matrix-assisted laser desorption/
ionization time-of-flight (MALDI-TOF) mass spectrometry
(MS), using the Sequenom MassARRAYtm methodology
(Sequenom Inc, San Diego, CA, USA). Amplification reac-
tions and parameters were based on the manufacturer’s
instructions.
2.3. Inflammatory markers
In all subjects, C-reactive protein (CRP) was measured
on stored (at 80 °C) and previously unthawed samples by
automated particle-enhanced immunoturbidimetric assay
(Roche UK, Welwyn Garden City, UK). The method has
inter- and intra-assay coefficients of variation of 3%. The
laboratory participates in the United Kingdom national ex-
ternal quality control for high-sensitivity CRP. Interleukin-6
(IL-6) was assayed using a high-sensitivity ELISA (R & D
Systems, Oxford, UK) with inter- and intra-assay coeffi-
cients of variation of 6%. All samples were processed by
technicians blinded to the identity of samples.
2.4. Cognitive function
The Mini-Mental State Examination (MMSE) was used
to measure global cognitive function. MMSE scores range
from zero points (very severe cognitive impairment) to 30
points (optimal cognitive function). Participants with poor
cognitive function (MMSE  24) were not eligible for
inclusion in the PROSPER study. Four neuropsychological
performance tests were used to measure various cognitive
domains. The Stroop-Colour-Word-test for attention and the
Letter-Digit Coding Test (LDT) for processing speed were
used to measure executive functioning. The outcome pa-
rameter for the Stroop test was the total number of seconds
to complete the third Stroop card containing 40 items. The
outcome variable for the LDT was the total number of
correct entries in 60 seconds. Memory was assessed with the
15-Picture Learning test (PLT) testing immediate and de-
layed recall. The main outcome parameters were the accu-
mulated number of recalled pictures over the three learning
trials and the number of pictures recalled after 20 minutes.
Reliability and sensitivity of these tests in an elderly pop-
ulation have been published elsewhere (Houx et al., 2002).
Cognitive function was tested at six different time points
during the study, at baseline, after 9, 18, and 30 months, and
at the end of the study. The time point of the last measure-
ment varied from 36 to 48 months from baseline; therefore,
we performed the analyses with their individually varying
time point but report the results for the mean of these time
points at 42 months. MMSE scores in this study population
were generally high (inclusion criteria MMSE  24 points)
nd changed only minimally over the time-course of the
tudy, therefore results of this cognitive assessment over the
ollow-up period are not reported here in view of likely
nsensitivity to change and ceiling effects.
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The primary endpoint in the study was the combined
endpoint of death from coronary heart disease (CHD), non-
fatal myocardial infarct (MI), and occurrence of clinical
stroke, either fatal or nonfatal. When death occurred after a
nonfatal stroke within a period of 28 days, it was regarded
as a fatal stroke. Secondary endpoints were the separate
coronary and cerebrovascular components of the primary
endpoint. Other study endpoints were occurrence of
transient ischemic attack, cancer incidence, and mortality.
Information on all deaths were received by postmortem
reports, death certificates, hospital records, general practi-
tioners’ records, and/or interviews of family members or
witnesses. All endpoints were adjudicated by the study
endpoint committee.
2.6. Statistical analysis
The program Haploview (Barrett et al., 2005) was used
to estimate the allele frequencies, test the consistency of the
genotype frequencies at each SNP locus with Hardy–Wein-
berg equilibrium, and estimate and plot pairwise linkage
disequilibrium (LD) between the SNPs. Haplotypes and
haplotype frequencies were calculated using SNPHAP
software (www-gene.cimr.cam.ac.uk/clayton/software). We
used multiple imputation analysis to deal with incomplete
data and to account for many haplotype probabilities per
subject. This method has been described elsewhere in more
detail (Harel and Zhou, 2007). Haplotypes with a frequency
of less than 5% were combined and included in all analyses,
without reporting the results. The haplotype analysis ap-
proach used in this study assumes an additive effect of the
haplotypes, and details of this approach have been described
elsewhere (Wallenstein et al., 1998).
The associations between the three LGALS3 polymor-
phisms and the inflammatory markers CRP and IL-6 were
assessed with linear regression adjusted for sex, age, and
country. Cross-sectional associations between the three
LGALS3 polymorphisms and cognitive function were as-
sessed with linear regression, adjusted for sex, age, educa-
tion, country, APOE phenotype, and version of test where
appropriate. The associations between the three genotypes,
the LGALS3 haplotypes, and cognitive function were lon-
gitudinally assessed with a linear mixed model for repeated
measurements without an interaction term for time and
genotype. The estimate for time represents the cognitive
decline per year. The results for the genotypes represent the
mean difference over time between the genotypes, which is
similar to a repeated cross-sectional analysis. All analyses
over time were adjusted for sex, age, education, country,
APOE phenotype, use of pravastatin, and version of test
where appropriate. The association between the genotypes
and clinical outcomes were assessed with Cox-proportional
hazard models adjusted for sex, age, country, and use of
pravastatin. The SPSS software (version 16.0, SPSS Inc,Chicago, IL, USA) was used for all statistical analyses.
P-values lower than 0.05 were considered statistically sig-
nificant.
3. Results
Genotyping of the three LGALS3 polymorphisms was
complete for 5675 subjects. The results of the remaining
129 subjects were missing because of insufficient DNA or
incomplete genotyping. All three SNPs were in Hardy–
Weinberg equilibrium (all p  0.05). Table 1 shows the
baseline characteristics of the 5675 participants divided
over the three countries. The mean age of all subjects at
study entry was 75.3 years, and about 50% of the partici-
pants were female. There were significant differences in
minor allele frequencies between the countries (p-value
chi-square  0.01). The three variants alleles of the
LGALS3 polymorphisms were significantly less common in
the Dutch subjects compared with the subjects from Scot-
land and Ireland. Therefore, we adjusted all analyses for
country to control for population stratification. Mean fol-
low-up of study subjects was 37 months (range 9–48
months).
To determine whether the polymorphisms in our study
sample were associated with inflammatory markers, we
assessed the difference in systemic levels of CRP and IL-6
over the three genotypes. Subjects carrying the variant allele
in any of the three polymorphisms had significantly higher
CRP levels compared with carriers of the wild-type allele
(p  0.01) (Table 2). We found no significant association
between the LGALS3 polymorphisms and IL-6 levels.
The results of the cross-sectional association between the
LGALS3 polymorphisms and cognitive function at baseline
are presented in Table 3. Significant associations were
found between all three variant genotypes and processing
speed and immediate memory (all p 0.04). Carriers of the
ariant alleles had significantly lower cognitive perfor-
ance on these neuropsychological performance tests com-
ared with wild-type carriers. Moreover, carriers of the
s1009977 allele also had lower attention (p  0.039). No
ssociation was found between the three LGALS3 polymor-
phisms and global cognitive function and delayed memory.
To investigate whether CRP levels is an intermediate factor
in the relation with cognitive function, we adjusted all
analyses for CRP levels and CRP genotypes. Adjusting for
CRP levels or CRP genotypes did not materially change the
results.
Table 4 shows the results of the association between the
LGALS3 polymorphisms and cognitive function over the
follow-up period. The term for time was significant for all
domains of cognitive function, indicating that all domains
declined over 42 months of follow-up. The estimates rep-
resent the mean difference in cognitive performance per
annum over time between the genotypes. Carriers of the
variant alleles significantly performed worse on the atten-
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rocessing speed and delayed memory, a similar trend was
bserved but not statistically significant. Again, adjusting
or CRP levels or CRP genotypes did not materially change
ur results (data not shown). The results of the analysis
etween the LGALS3 rs4644 polymorphism and the four
europsychological performance tests over time are graph-
cally displayed in Fig. 2.
The three SNPs were in strong LD and occurred together
n one haploblock (Fig. 1A). Three haplotypes were found
n our study population (Fig. 1B). All haplotypes with a
Table 1
Baseline characteristics of the participants of the PROSPER study per cou
Scotland (N  24
Continuous variates (mean, SD)
Age (years) 75.3 (3.4)
Body mass index (kg/m2) 26.7 (4.2)
Mini-Mental State Examination (points) 28.2 (1.5)
Total cholesterol (mmol/L) 5.7 (0.9)
LDL cholesterol (mmol/L) 3.8 (0.8)
HDL cholesterol (mmol/L) 1.3 (0.4)
LnCRP (mg/L) 1.1 (1.2)
LnIL6 (mg/L) 0.9 (0.6)
Categorical variates (n, %)
Female 1257 (51)
Current smoker 686 (28)
History of diabetes 206 (8)
History of hypertension 1408 (57)
History of myocardial infarction 369 (15)
History of vascular disease 1211 (49)
History of stroke or TIA 262 (11)
Genotype, minor allele frequency (%)a
LGALS3 rs4644 42
LGALS3 rs4652b 44
LGALS3 rs1009977c 42
a p-value chi-square 0.01 for the difference in allele frequencies betw
b The rs4652 SNP was measured in 5587 subjects.
c The rs1009977 SNP was measured in 5529 subjects.
Table 2
Association between three LGALS3 polymorphisms and inflammatory
arkers
Wt/Wt Wt/Var Var/Var p-value
trend
LGALS3 rs4644
N 1851 2788 1013
Log CRP 1.06 (0.03) 1.17 (0.02) 1.17 (0.04) 0.004
Log IL-6 0.96 (0.02) 0.99 (0.01) 0.97 (0.02) 0.419
LGALS3 rs4652
N 1714 2764 1085
Log CRP 1.07 (0.03) 1.15 (0.02) 1.18 (0.03) 0.008
Log IL-6 0.96 (0.02) 0.99 (0.01) 0.98 (0.02) 0.381
LGALS3 rs1009977
N 1758 2787 962
Log CRP 1.06 (0.03) 1.16 (0.02) 1.19 (0.04) 0.002
Log IL-6 0.96 (0.02) 0.99 (0.01) 0.98 (0.02) 0.261
P-value for trend was assessed with linear regression adjusted for sex, age,
and country.
Data are presented as mean (SE). Bold numbers indicate significant p-val-pues.requency above 5% were included in analyses. For analy-
is, we compared H222 with all three variant alleles present
ith H111, with no variants present, as reference haplotype.
n Table 5, the results of the association between the
GALS3 haplotypes and cognitive function during the fol-
ow-up period are shown. Again, the term for time was
ignificant for all domains of cognitive function, indicating
hat all domains declined over time. H222 with all the three
ariant alleles present was associated with worse cognitive
erformance on attention and immediate memory compared
ith the reference haplotype (all p  0.03). A similar trend
as also seen for the other cognitive domains, but did not
each statistical significance. As for the single SNP analysis,
he results remained similar when the analyses were done
ith adjustment for CRP levels or CRP genotypes (data not
hown).
In Table 6, the association between the LGALS3 poly-
orphisms and clinical endpoints is shown. No association
etween the three LGALS3 polymorphisms and any of the
linical endpoints was observed (all p  0.05).
. Discussion
In this study, we investigated the relation between
enetic variation in the LGALS3 gene, encoding for ga-
ectin-3, and cognitive function in an elderly cohort.
lthough observed differences were small, we found that
arriers of the variant alleles within the LGALS3 gene
erformed worse on the four neuropsychological perfor-
ance test compared with carriers of the wild-type allele,
Ireland (N  2139) The Netherlands (N  1082)
75.5 (3.3) 75.1 (3.3)
27.0 (4.3) 26.7 (3.8)
27.7 (1.6) 28.2 (1.5)
5.6 (0.9) 5.8 (0.9)
3.7 (0.8) 3.9 (0.8)
1.3 (0.4) 1.2 (0.3)
1.2 (1.0) 1.1 (1.0)
1.0 (0.7) 1.1 (0.7)
1168 (55) 513 (47)
573 (27) 265 (25)
215 (10) 182 (17)
1413 (66) 694 (64)
254 (12) 139 (13)
828 (39) 470 (43)
220 (10) 159 (15)
44 40
46 42
44 41
countries.ntry
54)
een therimarily at baseline. Because genetic variation within
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e adjusted the associations for CRP levels. After ad-
usting for CRP levels or CRP genotypes, there was still
n association between LGALS3 polymorphisms and cog-
itive function.
Our hypothesis was that galectin-3 has a regulatory role
n inflammation and could influence cognitive function at
ld age via this inflammatory role. We found that the three
GALS3 polymorphisms were indeed associated with high
RP levels, which could therefore fit our hypothesis that a
igh proinflammatory profile might lead to decreased cog-
itive performance at old age. However, adjustment of CRP
evels in the association between LGALS3 polymorphisms
nd cognitive function did not materially change our results.
f CRP would have been an intermediate phenotype and a
actor in the causal pathway, the association between
GALS3 and cognitive function would have disappeared
fter adjustment for CRP levels. Therefore, we conclude
hat CRP levels are not in the causal pathway.
The main route in which galectin-3 might be responsible
Table 3
Cross-sectional association between three LGALS3 polymorphisms and co
Wt/Wt Wt/Var
LGALS3 rs4644 (N) 1851 2788
Global function 28.04 (0.04) 28.05 (0.03
Attention 65.47 (0.61) 67.01 (0.54
Processing speed 23.41 (0.19) 22.93 (0.15
Immediate memory 9.45 (0.04) 9.27 (0.04
Delayed memory 10.26 (0.06) 10.06 (0.05
GALS3 rs4652 (N) 1714 2764
Global function 28.04 (0.04) 28.04 (0.03
Attention 65.48 (0.64) 67.21 (0.55
Processing speed 23.45 (0.20) 22.87 (0.15
Immediate memory 9.45 (0.05) 9.26 (0.04
Delayed memory 10.25 (0.07) 10.03 (0.05
GALS3 rs1009977 (N) 1758 2787
Global function 28.03 (0.04) 28.04 (0.03
Attention 65.41 (0.63) 66.95 (0.54
Processing speed 23.39 (0.20) 22.95 (0.15
Immediate memory 9.44 (0.05) 9.27 (0.04
Delayed memory 10.24 (0.06) 10.06 (0.05
ll p-values for trend were assessed with linear regression adjusted for se
est used.
ata are presented as mean (SE).
a Additionally adjusted for CRP levels.
Table 4
Association between LGALS3 polymorphisms and cognitive function over
Time Rs4644
Estimate (SE) p Estimate (S
ttention, seconds 0.65 (0.07) 0.001 1.02 (0.46
rocessing speeda 0.36 (0.01) 0.001 0.15 (0.12
Immediate memoryb 0.01 (0.01) 0.026 0.06 (0.03
Delayed memoryb 0.06 (0.01) 0.001 0.06 (0.04
Estimates and p-values were assessed with linear mixed models adjusted
appropriate, version of test used. Estimates were represented as mean diffe
a Assessed in number of digits.
b Assessed in number recalled.or cognitive function is via inflammation. Subjects with a
igh proinflammatory profile have an increased risk for
ognitive decline compared with subjects with an anti-in-
ammatory profile (Campbell et al., 1997; Ho et al., 2005).
alectin-3 has been shown to induce IL-2 production by
-cells, which lead to a higher proinflammatory state (Liu,
005). Moreover, galectin-3 is involved in many processes
uring the acute inflammatory response including neutro-
hil activation and adhesion, chemoattraction of monocytes
nd macrophages, opsonization of apoptotic neutrophils,
nd activation of mast cells (Henderson and Sethi, 2009).
lso, galectin-3 is highly expressed and secreted by mac-
ophages (Liu, 2005). A possible weakness of our study is
hat we have not measured galectin-3 in our study popula-
ion. In a previous study it was shown that subjects with
igh galectin-3 levels also have a high CRP level compared
ith subjects with low galectin-3 levels (de Boer et al.,
011). Because we have shown the association between the
GALS3 genetic variation and high CRP levels, we assume
at baseline
Var/Var p-value trend p-value trenda
1013
27.96 (0.05) 0.150 0.197
67.15 (0.91) 0.060 0.072
22.79 (0.25) 0.020 0.020
9.23 (0.06) 0.001 <0.001
10.13 (0.08) 0.074 0.033
1085
27.95 (0.05) 0.096 0.140
66.96 (0.87) 0.078 0.083
22.88 (0.24) 0.022 0.019
9.27 (0.06) 0.003 0.002
10.19 (0.08) 0.287 0.165
962
27.96 (0.05) 0.263 0.310
67.41 (0.96) 0.039 0.046
22.85 (0.26) 0.038 0.040
9.22 (0.06) 0.001 <0.001
10.13 (0.09) 0.109 0.048
ation, age, country, APOE phenotype, and where appropriate, version of
Rs4652 Rs1009977
p Estimate (SE) p Estimate (SE) p
0.027 0.93 (0.46) 0.045 1.03 (0.48) 0.031
0.203 0.13 (0.12) 0.283 0.11 (0.12) 0.365
0.043 0.06 (0.03) 0.080 0.06 (0.03) 0.064
0.187 0.04 (0.04) 0.367 0.05 (0.05) 0.300
, age, education, country, APOE phenotype, pravastatin use, and where
n cognitive performance per annum over the 42-months follow-up period.gnition
)
)
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ated with high galectin-3 levels as well.
Another mechanism besides inflammation can be
through the transcription factor cAMP response element-
binding protein (CREBBP). It has been shown that galec-
tin-3 is present in the hippocampal area and in the prefrontal
cortex of the brain (Wu et al., 2010; Satoh et al., 2011).
CREBBPs function as transcription factor in these areas is
galectin-3 dependent (Wu et al., 2010). It has been shown
that CBP/ mutant mice had normal short-term memory,
ut deficiencies in long-term memory, object recognition,
nd contextual memory tasks (Oike et al., 1999). Within the
ROSPER study, we have previously shown that genetic
ariation in the CBP gene, encoding CREBBP is also asso-
ciated with cognitive function (Trompet et al., 2011).
Galectin-3 has been associated with cardiovascular dis-
ease and, in particular, heart failure (de Boer et al., 2011;
Tang et al., 2011; Ueland et al., 2011). Within our study
population we did not observe an association between the
three LGALS3 polymorphisms and clinical outcomes. A
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H222 2 2 2  0.423 
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A
Fig. 1. Haplotype information. Figure (A) shows the linkage disequilibrium
the single nucleotide polymorphisms (SNPs) examined (zoomed picture).
haplotype frequencies. The two haplotypes (frequency 5%) were include
the reader is referred to the Web version of this article.possible explanation is that the observed association be- ttween galectin-3 concentrations and heart failure is dis-
turbed by reverse causality; by looking at the association
with genetic variation we overcome this problem. Another
possible explanation is that in this particular age-group, the
association with cardiovascular disease is not as clear as in
middle-age populations.
The three LGALS3 SNPs were chosen based on being
aplotype-tagging SNPs; by using these three tagging
NPs, we could form the two main haplotypes within the
GALS3 gene (which was confirmed with HapMap data).
ecause of the strong LD within the LGALS3 gene, we can
dentify the SNPs on these haplotypes. Two of the three
NPs we have chosen to genotype, rs4644 and rs4652, are
n the exonic region of the LGALS3 gene. Both polymor-
hisms are nonsynonymous and lead to an amino acid
hange (from proline to histidine and from threonine to
roline respectively). Although we do not know the result of
he amino acid changes on protein expression and protein
unctionality, we here suggest that carrying these variant
lleles might be associated with a decreased cognitive func-
the chromosomal region of the LGALS3 gene. There is strong LD between
Ps are in LD and occur together in one haploblock. Figure (B) shows the
analyses. For interpretation of the references to color in this figure legend,(LD) in
All SN
d in theion at old age.
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for this research question is that subjects were selected to
have a history of vascular disease or have an increased risk for
such a disease, and the results can only be extrapolated with
this in mind to the general population. Another possible weak-
ness is that the differences in cognitive function explained by
the genetic variation in the LGALS gene is only small, making
it difficult to use these results in clinical practice.
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Fig. 2. Representation of the longitudinal association between the LGALS3
dots with a straight line indicate the homozygous wild-type carriers; the
homozygous carriers of the variant allele are indicated by black triangles an
(bars).
Table 5
Association between LGALS3 haplotype and cognitive function over time
Time
Estimate (SE) p
All subjects
Attention, seconds 0.67 (0.07) 0.00
Processing speeda 0.36 (0.01) 0.00
Immediate memoryb 0.01 (0.01) 0.02
Delayed memoryb 0.06 (0.01) 0.00
Estimates and p-values were assessed with linear mixed models adjusted
APOE phenotype, pravastatin use, and where appropriate, version of test u
annum over the 42-months follow-up period.
a Assessed in number of digits.
b Assessed in number recalled.A major strength of our prospective study is our large
cohort size, with data on several measures of cognitive
function gathered serially in over 5000 subjects in three
different countries. Over a follow-up period of 42 months,
few subjects were lost to follow-up. As all subjects at study
entry had an MMSE of 24 points or greater, our observa-
tions are highly relevant to comparisons of cognitive change
in older people with good baseline cognitive functional
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Moreover, in previous studies it has been shown that from
70 years onwards there is substantial cognitive decline. All
subjects have significantly deteriorated in their cognitive
function within the 3 years of follow-up. We did not test for
an interaction between the genotypes and time because we
assumed that life time exposure of the polymorphisms
would have developed a difference in cognition already
earlier in life, therefore an additional decline in this elderly
population was not expected during our follow-up period.
In conclusion, based on our results, we suggest a possible
association between genetic variation in the LGALS3 gene
and cognitive function in an elderly population. The variant
alleles were associated with small differences in perfor-
mance on various cognitive function tests in the cross-
sectional analyses. Further research is warranted to assess
the functionality of these polymorphisms on protein expres-
sion and protein functionality. If differences in protein ex-
pression and functionality are indeed found between carriers
of the various SNPs, our findings might contribute to further
unravel the biology of cognitive decline and dementia.
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Table 6
Association between LGALS3 polymorphisms and clinical endpoints
rs4644
HR (95% CI) p
ardiovascular events 1.05 (0.96–1.15) 0.256
oronary events 1.03 (0.92–1.16) 0.566
erebrovascular events 0.99 (0.83–1.17) 0.870
eart failure hospitalization 1.00 (0.83–1.20) 0.963
ascular mortality 0.95 (0.80–1.12) 0.544
ll-cause mortality 1.00 (0.89–1.12) 0.972
ncident cancer 1.04 (0.91–1.19) 0.577
ancer mortality 1.06 (0.87–1.29) 0.592
azard ratios and p-values were assessed with Cox-proportional Hazard m
sed.This protection will comply with the consent signed for-mally at study entry by each subject, as well as to local,
national, and European standards for the protection of pri-
vacy and confidentiality.
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